进行性肺纤维化生理指标的性能特征
本研究为多中心回顾性队列分析,纳入美国、英国和加拿大2727例纤维化间质性肺疾病患者,评估8种FVC和DlCO下降分类指标及PPF指南标准对2年死亡或肺移植的区分能力;相对FVC下降≥10%、相对DlCO下降≥15%及PPF指南标准总体表现最佳,AUC为0.67-0.68,特异性高于敏感性。
要点
- 相对FVC下降≥10%、相对DlCO下降≥15%及PPF指南标准对2年死亡或肺移植区分能力最佳,AUC为0.67-0.68。
- 所有评估指标特异性均高于敏感性,相对肺功能下降指标优于绝对值指标。
- 单独相对FVC下降≥10%或DlCO下降≥15%的净获益与PPF指南标准相似。
核心结论
- 以单独FVC和DlCO下降指标分类PPF的临床效用与PPF指南标准相似。
- 表现最佳的生理学PPF指标区分结局具有高特异性但低敏感性。
研究设计与样本
- 多中心回顾性队列分析,纳入美国、英国和加拿大纤维化间质性肺疾病患者n=2,727。
- 评估8种FVC和DlCO下降分类指标及PPF指南标准对2年死亡或肺移植的区分能力。
- PPF指南标准要求以下两项:呼吸症状恶化、FVC绝对下降≥5%或DlCO≥15%、影像学进展。
- 使用决策曲线比较表现最佳指标用于指导治疗启动的净获益。
主要发现
- 相对FVC下降≥10%、相对DlCO下降≥15%及PPF指南标准总体测试性能最佳,AUC为0.67-0.68。
- 所有评估指标特异性高于敏感性,相对肺功能下降指标优于绝对值指标。
- 单独相对FVC下降≥10%和DlCO≥15%的净获益在治疗概率阈值范围内与PPF指南标准相似。
关键数值与推荐
- PPF指南标准:需满足以下两项——呼吸症状恶化、FVC绝对下降≥5%或DlCO≥15%、影像学进展。
- 相对FVC下降≥10%、相对DlCO下降≥15%及PPF指南标准的AUC为0.67-0.68。
临床怎么用
- 可考虑使用单独相对FVC下降≥10%或相对DlCO下降≥15%识别PPF,其临床效用与PPF指南标准相似。
- 应用这些生理学指标时需注意其高特异性但低敏感性,阴性结果不能排除进展风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Clinical measures of progressive pulmonary fibrosis (PPF) have been proposed, but their clinical utility remains unclear. Objectives: To determine performance characteristics of lung function-based PPF measures, including new guideline criteria for discriminating clinically relevant outcomes. Methods: A multicenter retrospective cohort analysis was performed to assess the performance characteristics of eight categorical measures of FVC and DlCO decline, together with PPF guideline criteria (requiring two of the following: worsening respiratory symptoms, absolute decline in FVC ⩾5% or DlCO ⩾15%, or radiological progression) for discriminating 2-year death or lung transplant among patients fibrotic interstitial lung disease from the United States, United Kingdom, and Canada (n = 2,727). The net benefit of the top-performing measures to inform treatment initiation were compared using decision curves. Measurements and Main Results: PPF classified according to relative decline in FVC of ⩾10%, relative decline in DlCO of ⩾15%, and PPF guideline criteria displayed the best overall test performance, with area under the receiver operating characteristic curves of 0.67-0.68. Specificity was higher than sensitivity for all evaluated measures, with relative measures of lung function decline outperforming absolute measures. The net benefit of standalone relative decline in FVC ⩾10% and DlCO ⩾15% was similar to PPF guideline criteria across the range of treatment probability thresholds. Conclusions: Classifying PPF by standalone measures of FVC and DlCO decline provides clinical utility similar to PPF guideline criteria. Top-performing physiology-based measures of PPF discriminate outcomes with high specificity but low sensitivity.
引用
- Newton CA, Thenappan A, Liu GY, et al. Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis. Am J Respir Crit Care Med. 2025. PMID: 40530983. doi:10.1164/rccm.202501-0317OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。